Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC20A2 | Q08357 | 1/20 | 0.52 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | USP8 | P40818 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | IDH2 | P48735 | 2/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3083591 | 0.92 | SLC20A2 (0.54) | SLC20A2SLC20A1PGRNR3C1AR | |
| SCHEMBL4781851 | 0.87 | AXL (0.49) | SLC20A2SLC20A1PGRNR3C1AR | |
| SCHEMBL4781931 | 0.84 | GAA (0.50) | PGRNR3C1ARESR2IDH2 | |
| SCHEMBL4779095 | 0.84 | MEN1 (0.57) | PGRNR3C1ARESR2GAA | |
| SCHEMBL30304653 | 0.84 | MEN1 (0.57) | PGRNR3C1ARESR2GAA | |
| SCHEMBL4779284 | 0.83 | AXL (0.51) | SLC20A2SLC20A1PGRNR3C1AR | |
| SCHEMBL7572438 | 0.82 | SLC20A2 (0.63) | SLC20A2SLC20A1PGRNR3C1AR | |
| SCHEMBL4725832 | 0.80 | LMNA (0.47) | PGRNR3C1ARESR2GAA | |
| SCHEMBL4846633 | 0.79 | SLC20A2 (0.49) | SLC20A2SLC20A1PGRNR3C1AR | |
| SCHEMBL4780290 | 0.78 | MEN1 (0.50) | SLC20A2SLC20A1PGRNR3C1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| WO-2008008374-A2 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | SLC20A2 2132/4885SLC20A1 2421/4885PGR 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.